{"name":"Apnimed","slug":"apnimed","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"AD109 dose2- B","genericName":"AD109 dose2- B","slug":"ad109-dose2-b","indication":"Narcolepsy","status":"phase_2"},{"name":"AD113","genericName":"AD113","slug":"ad113","indication":"Other","status":"phase_2"},{"name":"AD036","genericName":"AD036","slug":"ad036","indication":"Narcolepsy","status":"phase_2"},{"name":"AD109 dose1- A","genericName":"AD109 dose1- A","slug":"ad109-dose1-a","indication":"Narcolepsy","status":"phase_2"},{"name":"AD182","genericName":"AD182","slug":"ad182","indication":"Narcolepsy","status":"phase_2"},{"name":"AD313","genericName":"AD313","slug":"ad313","indication":"Other","status":"phase_1"},{"name":"AD504","genericName":"AD504","slug":"ad504","indication":"Narcolepsy","status":"phase_2"},{"name":"Period B","genericName":"Period B","slug":"period-b","indication":"Insomnia","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AD109","genericName":"AD109","slug":"ad109","indication":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Aroxybutynin and Atomoxetine","genericName":"Aroxybutynin and Atomoxetine","slug":"aroxybutynin-and-atomoxetine","indication":"Overactive bladder with urge incontinence","status":"phase_3"}]}],"pipeline":[{"name":"AD109 dose2- B","genericName":"AD109 dose2- B","slug":"ad109-dose2-b","phase":"phase_2","mechanism":"AD109 is a small molecule targeting the orexin receptor for the treatment of narcolepsy.","indications":["Narcolepsy"],"catalyst":""},{"name":"AD113","genericName":"AD113","slug":"ad113","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AD036","genericName":"AD036","slug":"ad036","phase":"phase_2","mechanism":"AD036 is a small molecule that targets the orexin receptor to treat narcolepsy.","indications":["Narcolepsy"],"catalyst":""},{"name":"AD109","genericName":"AD109","slug":"ad109","phase":"phase_3","mechanism":"AD109 is an adenosine A2A receptor antagonist that blocks inhibitory signaling in the tumor microenvironment to enhance immune cell activation.","indications":["Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"AD109 dose1- A","genericName":"AD109 dose1- A","slug":"ad109-dose1-a","phase":"phase_2","mechanism":"AD109 is a small molecule that targets the orexin receptor to treat narcolepsy.","indications":["Narcolepsy"],"catalyst":""},{"name":"AD182","genericName":"AD182","slug":"ad182","phase":"phase_2","mechanism":"AD182 is a small molecule targeting the orexin receptor for the treatment of narcolepsy.","indications":["Narcolepsy"],"catalyst":""},{"name":"AD313","genericName":"AD313","slug":"ad313","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AD504","genericName":"AD504","slug":"ad504","phase":"phase_2","mechanism":"AD504 is an oral small molecule that targets the orexin receptor to treat narcolepsy.","indications":["Narcolepsy"],"catalyst":""},{"name":"Aroxybutynin and Atomoxetine","genericName":"Aroxybutynin and Atomoxetine","slug":"aroxybutynin-and-atomoxetine","phase":"phase_3","mechanism":"This combination drug blocks muscarinic acetylcholine receptors (via oxybutynin component) and inhibits norepinephrine reuptake (via atomoxetine component) to reduce urinary incontinence and improve attention.","indications":["Overactive bladder with urge incontinence","Neurogenic detrusor overactivity (likely, given atomoxetine component)"],"catalyst":""},{"name":"Period B","genericName":"Period B","slug":"period-b","phase":"marketed","mechanism":"Period B is a melatonin receptor agonist that helps regulate sleep-wake cycles.","indications":["Insomnia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"pipeline","source":"Indian Pharma Post","summary":"Apnimed secures $150 million financing to fuel US launch of oral sleep apnea drug AD109 - Indian Pharma Post","headline":"Apnimed secures $150 million financing to fuel US launch of oral sleep apnea drug AD109","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNek01WDMweU9WS0ZfY0ota1c1WmVHRkdncHMzRUx2cFhGVnNkaHRKV09KNFFJOWtvMXlvNkdpQkU3cndNM1lVbmdHUkhHaDE4WFdDbFExSVF0RVh6T0pkeENIbTl2cUhLWEUtM3dIT181bF9jR3FVcTdXeEJpX0cyN203aVRQVTlQMjFEZDEwM0lMV0tzTXUtQnk1RU5GWU85WERLMTNhcUc2RW04Tl8yRGhwdmpnQ2VDb05RYjZLZ3ROSVdRR0NVWXV6bnJtY3A0OUE?oc=5","date":"2026-03-25","type":"deal","source":"Pharmaceutical Executive","summary":"Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science - Pharmaceutical Executive","headline":"Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5BMExwQnE0S0U4aGF3QXJnVnN6b3o0R25yRERMS2VwcXBhSjVVRjJPNTR3VWY4c2dYWFBFSkFnWGVqbkc0M3BBQ3B4anExbjNxOFRQcUxSU3V2V1YwUDlhUDBVNmZzcnNUQ3F0ekotbUVVU0ROZmdWLWRGZw?oc=5","date":"2026-03-25","type":"deal","source":"The Pharma Letter","summary":"Shionogi to buy out Apnimed stake in JV - The Pharma Letter","headline":"Shionogi to buy out Apnimed stake in JV","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9KZHZvWXRWTlpURDNuWUdSVUREVlVDUll2bGcyVXhTMDFWaU1KZVBYME91a184em9Tb3NUUzFNd2VUM19MeVJ1NXZhQjFtV2RFVEp3?oc=5","date":"2026-03-24","type":"deal","source":"FirstWord Pharma","summary":"Shionogi buys out Apnimed's stake in sleep-focused joint venture for $100M - FirstWord Pharma","headline":"Shionogi buys out Apnimed's stake in sleep-focused joint venture for $100M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOeHg4UTFxM0VWS0U3S3g2R1A2M1VxNzJPdUdhUHcxdGdtdngzLVFzSTRYekpSSUFMZkRLSUJMQ2thVm5KTU1aRXM4RW9HTWo5TU1fdVZFZ2hzZzU0WTFjTlpiNHdHeVFFa3lhU1BBcENodDJUdXMxQ01PSDRkanlKLWNwaV8tbC1pelpaLXFTMHE1cGtjSy0taU4tVS00Q05CaG95X0xxYkZjdldMWnBnZTEyUk5jNmNVV1E?oc=5","date":"2026-03-24","type":"regulatory","source":"AD HOC NEWS","summary":"Shionogi & Co Ltd stock surges on $100M Apnimed deal and Xocova approval boost - AD HOC NEWS","headline":"Shionogi & Co Ltd stock surges on $100M Apnimed deal and Xocova approval boost","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQNXlMcTNWZUFkcmk1dW4wWUZwU3F1U0lDa1hFS2pLTU1FUExLb1dJWERrSUFXU1FDa0hZLVdXMnhWcURUSkxGSUR6STk3N21NNjlXd3Y0RlNMdjFNeG45bXNMSWJ5a2FJMnlybVVTRnBPY0tqa3J6dFJfYkVxYWZLX0cxR2xCcU1uQmxxSmdn0gGTAUFVX3lxTFA0MExSMHVoSnozMEpJRXNfNnJiU1Y0QzZ2V2tfX3ZlSU9DSDNiMVQyWlBfZE5oVVpYWDJFMzRRY2s4eHlIbURLQ0tuNVVQRnBfUndzZzN2dmM3QUpLalF2MGhHT2ZaY1lXRWRCdTBjQ0VQWG94Z1pEMDl0TTZxbVZZM3VhaUVOd043bml6eDF6LWxScw?oc=5","date":"2026-02-11","type":"pipeline","source":"ABC News","summary":"1st pill for obstructive sleep apnea could be around the corner - ABC News","headline":"1st pill for obstructive sleep apnea could be around the corner","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBDdjF6cUh3NE9adTU5Vzd0eTVkRXdSV1UxeV80d1JIdVRNSmtHZUV1aWNJbkt1T0lYYUFjaThOWWVMTEZkaXgtakg5UV9odllESUd3dDRJdC1mNHg0NDZLOUxHUm5tZzYzWFRxWDRTVzNtV0U?oc=5","date":"2026-01-16","type":"pipeline","source":"Pharmaceutical Executive","summary":"Must Watch Milestones for Apnimed in 2026 - Pharmaceutical Executive","headline":"Must Watch Milestones for Apnimed in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQbkM3SEpiNnQwaVBrVWk4Z1ZzMnlLbHlWM1hiSWU3QWgwVVJRaXF4elU0Q1ZyZjJ2ZWJRU1V2TWJnYjB0Z1A3TnRnMDVsYjY1WkZ4WS11azRycFpFVlgzQ284eC1UbkF4QkR0VER6MGlmYkljNnRMVjJUUTlsYVJCa3FsNDhpWTdKZFFrN3pBQjBrc1h3MUhMTg?oc=5","date":"2025-09-02","type":"trial","source":"BioWorld News","summary":"Phase III wins in July include Apnimed, Livzon, Takeda - BioWorld News","headline":"Phase III wins in July include Apnimed, Livzon, Takeda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPWFdsM0FnSThqYkVwUGhSNE9YUW1QbHVWbzl1a1R3a3J4SHlLU256T2I4Q0ZjUXR5LWlrZm5STnJ1Uy1yOFUtc3VvSlMxZWRJNUIxOHE4aVJ0dkYyZ2hQdjlUWXlkWDVkcW94M01yb1lrVGViUHg4eXg3WEt2TTJmenpWdlQ4dlF0TUFrQnpTUQ?oc=5","date":"2025-07-29","type":"pipeline","source":"masslive.com","summary":"Cambridge startup’s sleep apnea pill shows promising results - masslive.com","headline":"Cambridge startup’s sleep apnea pill shows promising results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1IR0VZTThmQjRkMGNJMVdQUnFmMDQ1QzMxQ3BMMzlCOFV5dGVZYWJXWXczUmlNenU4djF5R2trOU9kQUxfMDlxTm9ueWttNlpuNExR?oc=5","date":"2025-07-23","type":"trial","source":"FirstWord Pharma","summary":"Apnimed firms up filing plans for oral sleep apnoea drug after second pivotal study win - FirstWord Pharma","headline":"Apnimed firms up filing plans for oral sleep apnoea drug after second pivotal study win","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNYWFHd1B4c244RHhzWW9IRE5veVowNU9WNW9rd2ROZUVTdjNBSkNINm8tQmo5TU94b0l2d0xFRDlvS3ZDYUhfU0JNakNVVFFja1lteGFGZl9kMXB1aEx1X05QVmh5Ylp2U0ZlZXhjZFV4UF92VzRGUTVXZ3ZJQkNaaEVESzJIMDROUjYtNk9MTTZkZzdXYTcyZnZEOWRhRGVLS2VQS0Exel9Wam1Ybmc?oc=5","date":"2025-07-23","type":"trial","source":"Fierce Biotech","summary":"Apnimed's sleep apnea asset goes 2 for 2 in phase 3, solidifying star potential - Fierce Biotech","headline":"Apnimed's sleep apnea asset goes 2 for 2 in phase 3, solidifying star potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQbFFCTFRUUGZnRHJLa3BaRmJaSll2R1dzTzBZWkN0YmEtcXd0a2ZGcDhIcng4aUZ1U2htRzRFcWNGSWVuel9fXzM5QTZkTVMwSllDejZEZDhfMUJPMTMyM0h6SG43b3NicWhUb1BZYkdOSV9FaVJNZXhveHVqcm5sZzFpVWNndHpfTnlDVW9CbXFkZmZEdkpXSWc2RQ?oc=5","date":"2025-05-20","type":"trial","source":"The Pharma Letter","summary":"Apnimed touts Phase III success for first-ever sleep apnea pill - The Pharma Letter","headline":"Apnimed touts Phase III success for first-ever sleep apnea pill","sentiment":"positive"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_2":6,"phase_3":2,"phase_1":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}